

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Antiviral Activity of 1,2-Carbonucleosides

L. Santana^a; M. Teijeira^a; E. Uriarte^a; J. Balzarini^b; E. De Clercq^b

^a Facultad de Farmacia, Universidad de Santiago de Compostela, España ^b Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Santana, L. , Teijeira, M. , Uriarte, E. , Balzarini, J. and De Clercq, E.(1995) 'Synthesis and Antiviral Activity of 1,2-Carbonucleosides', *Nucleosides, Nucleotides and Nucleic Acids*, 14: 3, 521 — 523

To link to this Article: DOI: 10.1080/15257779508012417

URL: <http://dx.doi.org/10.1080/15257779508012417>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

BIOLOGICAL ACTIVITY

**SYNTHESIS AND ANTIVIRAL ACTIVITY OF
1,2-CARBONUCLEOSIDES**


L. Santana^a, M. Teijeira^a, E. Uriarte^{a*}, J. Balzarini^b and E. De Clercq^b

a) Facultad de Farmacia, Universidad de Santiago de Compostela, 15706 Santiago de Compostela, España. b) Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000, Leuven, Belgium.

Abstract: Members of a new class of carbonucleoside analogues (OTC, one two substituted carbonucleosides) were synthesized and evaluated against HIV.

On the basis of our theoretical studies in the area of nucleoside analogues, we decided to prepare a series of new carbocyclic analogues in which the hydroxymethyl and pyrimidine base substituents on the cyclopentane ring are adjacent and in *cis* and *trans* position, with the base directly linked to the ring or separated from it by a methylene group (compounds **1-6**). The starting aminoalcohols were obtained by a simple, readily generalizable route from ethyl 2-oxocyclopentanecarboxylate; their stereochemistry was confirmed by NMR spectroscopy and alternative synthesis¹. Compounds **1**, **3** and **5** were synthesized from racemic mixtures of the corresponding aminoalcohols by treatment with 3-ethoxy-2-propenoyl isocyanate² in dimethylformamide at room temperature³, followed by cyclization of the resulting di-substituted urea in refluxing sulfuric acid medium (65 - 70% overall yield)⁴. Compounds **2**, **4** and **6** were synthesized by treatment of **1**, **3** or **5** with iodine - nitric acid in dioxane⁵ (90% yield⁶); see Scheme 1.

In this series, only compound **4** showed antiviral activity at a concentration below 100 $\mu\text{g} / \text{mL}$, its EC_{50} for inhibiting both HIV-1- and HIV-2-induced giant cell formation in



a) 3-Ethoxy-2-propenoyl isocyanate, DMF b) Sulfuric acid (1M) c) Iodine, nitric acid, dioxane

SCHEME 1

TABLE 1. Anti-HIV-1 and -HIV-2 activity and cytotoxic properties of compounds **1** - **6** in human T-lymphocyte (CEM) cells

Compound	EC ₅₀ ^a (μg/mL)		CC ₅₀ ^b (μg/mL)
	HIV-1	HIV-2	
1	> 100	> 100	> 100
2	> 100	> 100	> 100
3	> 100	> 100	> 100
4	12.5 ± 3.5	12.5 ± 3.5	68.7 ± 44.3
5	> 100	> 100	> 100
6	> 100	> 100	> 100

^a50% Effective concentration, or concentration required to protect CEM cells against the cytopathogenicity of HIV by 50%.

^b50% Cytotoxic concentration, or concentration required to reduce CEM cell viability by 50%.

CEM cells being 12.5 μg / mL . The toxicity of this compound (CC₅₀) was 69 μg / mL in the same cell line (TABLE 1).

Acknowledgement

We thank the DGICYT (PM92-0090) and Xunta de Galicia (XUGA20312B92) for partial financial support.

REFERENCES AND NOTES

1. L. Santana, M. Teijeira, M. C. Terán and E. Uriarte, VIII Congreso Soc. Esp. Química Terapéutica. Salamanca (España), Sept-Oct, 1993.
2. Y. F. Shealy and C. A. O'Dell, *J. Heterocyclic Chem.*, 1976, **13**, 1015.
3. L. J. J. Hrunowski and W. A. Szarek, *Can. J. Chem.*, 1985, **63**, 2787.
4. All compounds had spectral and analytical data consistent with their structures.
5. P. Herdewijn, E. De Clercq, J. Balzarini and H. Vanderhaeghe, *J. Med. Chem.*, 1985, **28**, 550.
6. All these compounds were purified by FC using 1:1 hexane/ethyl acetate, and had spectral and analytical data consistent with their structures.